# EDGAR Filing Document

**Accession Number:** 0001559356
**File Stem:** 0001493152-23-000111
**Filing Date:** 2023-1
**Character Count:** 10601
**Document Hash:** d12149bc57f67057e909dd70a2241d46
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-000111.hdr.sgml**: 20230103

**ACCESSION NUMBER**: 0001493152-23-000111

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230103

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230103

**DATE AS OF CHANGE**: 20230103

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immune Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001559356
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 593226705
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-54933
- **FILM NUMBER:** 23501991

**BUSINESS ADDRESS:**
- **STREET 1:** 2431 ALOMA AVE #124
- **CITY:** WINTER PARK
- **STATE:** FL
- **ZIP:** 32792
- **BUSINESS PHONE:** (888) 613-8802

**MAIL ADDRESS:**
- **STREET 1:** 2431 ALOMA AVE #124
- **CITY:** WINTER PARK
- **STATE:** FL
- **ZIP:** 32792

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TNI BIOTECH, INC.
- **DATE OF NAME CHANGE:** 20121001

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 3, 2023 (December 31, 2022)

---

| |
|:---|
| **IMMUNE THERAPEUTICS, INC.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Florida** | **000-54933** | **59-3226705** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (IRS Employer <br> Identification No.) |

---

---

| | |
|:---|:---|
| **2431 Aloma Ave.** **, Suite 124, Winter Park, Florida** | **32792** |
| (Address of principal executive offices) | (Zip Code) |

---

---

| |
|:---|
| **888** **-391-9355** |
| (Registrant's telephone number, including area code) |

---

  <br> (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

***Resignation of Kevin Phelps as Director***

 ****

On December 15, 2022, Kevin Phelps, a director of the Company, delivered a letter of resignation to the Company, pursuant to which Mr. Phelps resigned from his position as a director of the Company, effective December 31, 2022. Mr. Phelps' resignation was not the result of any material dispute or disagreement with the Company, the Company's management, or the Company's Board on any matter relating to the operations, policies or practices of the Company. A copy of the letter of resignation of Mr. Phelps is attached hereto as Exhibit 17.1.

 **

***Resignation of Dr. Roscoe Moore as Director***

 **

On December 17, 2022, Dr. Roscoe Moore, a director of the Company, delivered a letter of resignation to the Company, pursuant to which Dr. Moore resigned from his position with the Company, effective on December 31, 2022. Dr. Moore's resignation was not the result of any material dispute or disagreement with the Company, the Company's management, or the Company's Board on any matter relating to the operations, policies, or practices of the Company. A copy of the letter of resignation of Dr. Moore is attached hereto as Exhibit 17.2.

The Company will provide Mr. Phelps and Mr. Moore with copies of the disclosures it is making in this Item 5.02 no later than the day the Company files the disclosures with the SEC. The Company will provide Mr. Phelps and Dr. Moore with the opportunity to furnish the Company, as promptly as possible, with a letter addressed to the Company stating whether Dr. Moore or Mr. Phelps agrees with the statements made by the Company in this Item 5.02 and, if not, stating the respects in which he does not agree. The Company will file any letter provided by Mr. Phelps or Dr. Moore in relation thereto by amendment to this Current Report within two business days after receipt by the Company.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| 17.1 | [Resignation Letter of Mr. Kevin Phelps, dated December 15, 2022](ex17-1.htm) |
| 17.2 | [Resignation Letter of Dr. Roscoe Moore, dated December 17, 2022](ex17-2.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Date: January 3, 2023 | IMMUNE THERAPEUTICES, INC. |
|  | */s/ Kelly O. Wilson* |
|  | Name: Kelly O. Wilson |
|  | Title: Interim Chief Executive Officer, Interim President, and Chief Operating Officer |

---

## Exhibit 17.1

**Exhibit 17.1**

**Kevin J. Phelps**

**14 Oakfield Way** 

**Pittsford, New York 14534** 

585-820-5474

December 15, 2022

Ms. Kelly Wilson

President and CEO

Immune Therapeutics, Inc.

2431 Aloma Avenue #124

Winter Park, Florida 32792

Dear Ms. Wilson:

Please accept this letter as formal notification of my intent to resign from my position as a member of the Board of Directors of Immune Therapeutics, Inc. (the "Company") effective December 31, 2022.

Following the Company' recapitalization earlier this year, it has become clear that the strategic direction of the Company is in transition and a revamped Board composition is better able to lead and support the Company's new direction. As such, in the best interests of the Company and its shareholders, I submit my calendar year-end resignation at this time.

It has been a pleasure to serve as a Director for the past four years and I leave with best wishes for the Company's continued success.

This will also confirm that while such resignation shall terminate all future Board-related equity, compensation and expense related obligations of the Company following the above-stated effective date, compensation in the amount of $30,000 and stock grants due in connection with my previous and current Board membership under my Board services contract shall remain due and owing and a legal obligation of the Company. Such compensation shall be paid in cash (or in lieu thereof the issuance of a mutually acceptable 12-month promissory note bearing a 6 percent interest rate) and all applicable shares shall be issued on or before the effective date of my resignation.

My resignation is also contingent on the Company's releasing me, discharging me, and holding me harmless from any and all personal liability for actions or inactions related to my Board membership for the period up to and including the effective date of my resignation.

If I can be of assistance to the Company in any fashion in the future, feel free to reach me at the contact information listed above.

Sincerely,

*/s/ Kevin Phelps*

## Exhibit 17.2

**Exhibit 17.2**

**Roscoe Moore DVM, MPH, PhD,** 

**14315 Artic Ave, Rockville, MD 20853-2253**

**(301) 8711134**

<u>rmoore@phrockwood.com</u>

December 17, 2022

Ms. Kelly Wilson

President and CEO

Immune Therapeutics, Inc.

2431 Aloma Avenue #124

Winter Park, Florida 32792

Dear Ms. Wilson:

Please accept this letter as formal notification of my intent to resign from my position as a member of the Board of Directors of Immune Therapeutics, Inc. (the "Company") effective December 31, 2022.

Following the Company' recapitalization earlier this year, it has become clear that the strategic direction of the Company is in transition and a revamped Board composition is better able to lead and support the Company's new direction. As such, in the best interests of the Company and its shareholders, I submit my calendar year-end resignation at this time.

It has been a pleasure to serve as a Director for the past five years and I leave with best wishes for the Company's continued success.

This will also confirm that while such resignation shall terminate all future Board-related equity, compensation and expense related obligations of the Company following the above-stated effective date, compensation in the amount of $50,000 and stock grants due in connection with my previous and current Board membership under my Board services contract shall remain due and owing and a legal obligation of the Company. Such compensation shall be paid in cash (or in lieu thereof the issuance of a mutually acceptable 12-month promissory note bearing a 6 percent interest rate) and all applicable shares shall be issued on or before the effective date of my resignation.

My resignation is also contingent on the Company's releasing me, discharging me, and holding me harmless from any and all personal liability for actions or inactions related to my Board membership for the period up to and including the effective date of my resignation.

If I can be of assistance to the Company in any fashion in the future, feel free to reach me at the contact information listed above.

Sincerely,

*/s/ Roscoe Moore, DVM*